Oxymetholone

Prostate and breast cancer, nephrosis. Severe hepatic impairment. Pregnancy and lactation.

Patient w/ oedematous conditions (e.g. migraine, seizure disorder, CV disease), DM. Renal and mild to moderate hepatic impairment. Childn. Monitoring Parameters Periodically monitor LFT, lipid profile, serum iron and iron binding capacity, Hb and haematocrit levels. Monitor radiologic examination of bones every 6 mth (prepubertal childn); urine and serum Ca, signs of virilisation in female patient treated for breast cancer.

Significant: Benign hepatic tumours, blood lipid changes, mild virilisation, benign prostatic hypertrophy (elderly males), clotting factor alterations. Nervous: Excitation, insomnia, deepening of voice (female). CV: Coronary artery diseas, peripheral oedema. GI: Nausea, vomiting, diarrhoea. Hepatic: Reversible changes in hepatic function tests (e.g. increased serum bilirubin, alkaline phosphatase and glutamic-oxaloacetic transaminase, increased Bromsulphalein retention). Genitourinary: Increased creatine and creatinine excretion, phallic enlargement, increased erections (prepubertal males), erectile dysfunction, testicular atrophy and oligospermia, impotence, chronic priapism, testicular disease, epididymitis, bladder irritability, decreased seminal volume, clitoromegaly, menstrual disease, amenorrhea (female). Endocrine: Increased or decreased libido, decreased glucose tolerance, gynecomastia, hirsutism (female). Haematologic: Iron-deficiency anaemia, haemorrhage, leukemia, prolonged prothrombin time (PT). Musculoskeletal: Muscle cramps, increased creatinine phosphokinase, premature closure of epiphyses (childn). Dermatologic: Acne, androgenic alopecia, hyperpigmentation. Others: Chills, oedema, serum electrolytes retention.
Potentially Fatal: Peliosis hepatitis, malignant hepatic tumours, cholestatic jaundice w/ hepatic necrosis.

Increased fluid-retention effect w/ adrenal steroids or ACTH. May enhance anticoagulant effect (e.g. increased INR/PT) of warfarin. May increase hepatotoxic effect of cyclosporine. May enhance hypoglycaemic effect of blood glucose lowering agents. May increase risk of cholestasis of ajmaline.

Anabolic Agents

A14AA05 - oxymetholone ; Belongs to the class of androstan derivative anabolic steroids used as systemic anabolic agents.